Multianalyte sensor

• US 20060078908A1
• Filed: 06/07/2005
• Published: 04/13/2006
• Est. Priority Date: 06/09/2004
• Status: Active Grant

• Current Assignee: Becton, Dickinson & Co
• Original Assignee: Becton, Dickinson & Co
• Inventors: Pitner, James Bruce, Vonk, Glenn
• Granted Patent: US 7,951,605 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: G01N 33/54366 Apparatus specially adapted for solid-phase testing
• CPC Class Codes: G01N 33/544 the carrier being organic
• CPC Class Codes: G01N 33/66 involving blood sugars, e.g. galactose
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743
• CPC Class Codes: Y10T 436/144444 Glucose

Abstract

The invention relates to devices for continuously measuring the concentrations of more than one target analyte. Specifically, the devices comprise a plurality of analyte binding domains, with each domain being capable of specifically and reversibly binding to at least one of the target analytes. The devices further comprise a membrane surrounding these binding domains that is permeable to the target analytes. The devices convey binding information to a detector. The invention also relates to methods of using the devices, including monitoring chronic disease states in an individual.

Claims

1. A device for measuring the concentrations of more than one target analyte, said device comprising

a) a plurality of analyte binding domains, wherein each of said analyte binding domains is capable of specifically and reversibly binding to at least one of said target analytes;

and

b) a membrane surrounding said binding domains, said membrane being permeable to said target analytes;

said device being capable of conveying to a detector the presence or absence of binding of said target analytes to said binding domains.

2. The device of claim 1, wherein said device is capable of continuously conveying to a detector the presence or absence of binding of said target analytes to said binding domains.

3. The device of claim 1, wherein said target analytes are selected from the group consisting of amino acids, peptides, polypeptides, proteins, carbohydrates, lipids, nucleotides, oligonucleotides, polynucleotides, glycoproteins, proteoglycans, lipoproteins, drugs, drug metabolites, small organic molecules, inorganic molecules, polymers and combinations thereof.

4. The device of claim 3, wherein one of said target analytes is selected from the group consisting of fatty acids, lactate, C-reactive protein, and glucose.

5. The device of claim 4, wherein said target analytes are at least fatty acids, lactate and glucose.

6. The device of claim 5, wherein one or more polypeptides or proteins comprise said plurality of analyte binding domains.

7. The device of claim 6, wherein at least of one of said one or more polypeptides or proteins are selected from the group consisting of galactose/glucose binding protein (GGBP), maltose binding protein (MBP), ribose binding protein (RBP), arabinose binding protein (ABP), dipeptide binding protein (DPBP), glutamine binding protein (QBP), iron binding protein (FeBP), histidine binding protein (HBP), phosphate binding protein (PhosBP), oligopeptide binding protein (OppA) and a fatty acid binding protein (FABP) and derivatives thereof.

8. The device of claim 7, wherein said one or more polypeptides or proteins are GGBP, a FABP and a GGBP derivative.

9. The device of claim 8, wherein said target analytes are at least two selected from the group consisting of glucose, fatty acids and lactate.

10. The device of claim 9, wherein said at least two analytes are glucose and fatty acids.

11. The device of claim 9, wherein said at least two analytes are glucose and lactate.

12. The device of claim 11, wherein said polypeptides or proteins further comprise at least one label.

13. The device of claim 12, wherein said at least one label is selected from the group consisting of a fluorescent label, a phosphorescent label, a chemiluminescent label, a bioluminescent label and an electrochemical label.

14. The device of claim 12, wherein said membrane comprises a lipid.

15. The device of claim 14, wherein said lipid is a glycerophospholipid.

16. The device of claim 15, wherein said glycerophospholipid is selected from the group consisting of a phosphatidylcholine, a phosphatidylethanolamine, a phosphatidylserine

17. The device of claim 12, wherein said membrane comprises a polymer.

18. The device of claim 16, wherein said polymer comprises a compound selected from the group consisting of polyvinyl alcohol, polyacrylamide, polyN-vinyl pyrolidone, polyethylene oxide, polyhydrolysed acrylonitrile, polyacrylic acid, polymethacrylic acid, polyhydroxyethyl methacrylate (polyHEMA), polymethyl methacrylate (polyMMA), polyurethane, polyethylene amine, polyethylene glycol, polymethacrylate-phosphorylcholine (polyMPC), polylauryl methacrylate (polyLMA), hydroxyethyl methacrylate-methyl methacrylate copolymer (polyHEMA-MMA), tetramethyl orthosilicate, tetraethyl orthosilicate, cellulose, cellulose acetate, carboxy methyl cellulose, alginic acid, pectinic acid, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, collagen, pullulan, gellan, xanthan, carboxymethyl dextran, chondroitin sulfate, cationic guar, cationic starch as well as salts and esters thereof.

19. A method of monitoring the metabolic substrate levels in a subject comprising implanting the device of claim 2 in said subject to allow measurement of said substrate levels, and collecting said measurements of said substrate levels.

20. A method of monitoring diabetes in a subject comprising implanting the device of claim 2 in said subject, wherein one of said target analytes is selected from the group consisting of fatty acids, lactate, and glucose.

21. The method of claim 19, wherein one of the target analytes is glucose.